Arcturus Therapeutics Holdings Inc. (ARCT) Bundle
Understanding Arcturus Therapeutics Holdings Inc. (ARCT) Revenue Streams
Understanding Arcturus Therapeutics Holdings Inc.’s Revenue Streams
The following table summarizes the total revenues for Arcturus Therapeutics Holdings Inc. for the periods indicated:
| Period | 2024 Revenue (in thousands) | 2023 Revenue (in thousands) | $ Change | % Change |
|---|---|---|---|---|
| Three Months Ended September 30 | $41,673 | $45,140 | $(3,467) | -7.7% |
| Nine Months Ended September 30 | $129,544 | $135,944 | $(6,400) | -4.7% |
Revenue decreased by $3.5 million during the three months ended September 30, 2024, compared to the same period in 2023. This decline was primarily due to a lower milestone achievement from the CSL agreement during the third quarter of 2024. However, this decrease was partially offset by revenue recognized from a supply agreement related to the commercial production of KOSTAIVE® and an increase in revenue from the BARDA agreement during the same period.
For the nine months ended September 30, 2024, revenue decreased by $6.4 million relative to the same period in 2023. The decrease was attributed to the timing and value of milestone achievements and the recognition of a conditional payment during the prior year, although it was offset by revenue from supply agreements in the current year.
Contribution of Different Business Segments to Overall Revenue
The revenue breakdown for the three and nine months ended September 30 is as follows:
| Type of Revenue | Three Months Ended September 30, 2024 (in thousands) | Three Months Ended September 30, 2023 (in thousands) | Nine Months Ended September 30, 2024 (in thousands) | Nine Months Ended September 30, 2023 (in thousands) |
|---|---|---|---|---|
| Collaboration Revenue | $38,815 | $43,376 | $117,389 | $132,670 |
| Grant Revenue | $2,858 | $1,764 | $12,155 | $3,274 |
The collaboration revenue primarily comes from the CSL Seqirus agreement, which includes upfront payments and milestone payments associated with the development of vaccines. The grant revenue is derived from agreements with government entities, notably BARDA, which supports research and development initiatives.
Analysis of Significant Changes in Revenue Streams
During the third quarter of 2024, the company recognized a $25.0 million development milestone related to the CSL Collaboration Agreement, which is anticipated to be received in the fourth quarter of 2024. Additionally, the total deferred revenue as of September 30, 2024, was $40.3 million, down from $87.1 million as of December 31, 2023, reflecting a decrease in expected future revenue recognition from prior collaboration agreements.
Moreover, the company received an advance payment of $23.6 million in 2023 for the manufacturing and supply of the ARCT-154 drug product, with $18.0 million recognized in revenue during the second quarter of 2024.
This analysis indicates that the company's revenue streams are influenced by a combination of collaboration agreements, milestone achievements, and government grants, with fluctuations largely tied to the timing of these payments and the progress of development projects. The ongoing partnerships and contracts will be critical in shaping future revenue growth and stability.
A Deep Dive into Arcturus Therapeutics Holdings Inc. (ARCT) Profitability
A Deep Dive into Arcturus Therapeutics Holdings Inc. Profitability
Gross Profit Margin: For the nine months ended September 30, 2024, the total revenue was $129.544 million with operating expenses amounting to $191.819 million, leading to a gross profit margin of approximately 33.6% for the period.
Operating Profit Margin: The loss from operations for the same period was $(62.275 million), resulting in an operating profit margin of approximately -48.2%.
Net Profit Margin: The net loss for the nine months ended September 30, 2024, was $(50.936 million), translating to a net profit margin of approximately -39.3%.
Trends in Profitability Over Time
In comparing the current nine-month period to the same period in 2023, total revenue decreased from $135.944 million to $129.544 million, a decline of approximately 4.3%. Operating expenses decreased from $195.877 million to $191.819 million, reflecting a reduction of about 2.1%. The net loss increased from $(18.018 million) in 2023 to $(50.936 million) in 2024, indicating a significant deterioration in profitability.
Comparison of Profitability Ratios with Industry Averages
As of 2024, the average net profit margin for biotechnology companies is approximately -20%. In contrast, Arcturus Therapeutics' net profit margin stands at -39.3%, indicating underperformance relative to industry peers.
Analysis of Operational Efficiency
Cost Management: The total operating expenses for the first nine months of 2024 were $191.819 million, a slight decrease compared to $195.877 million in 2023. However, the persistent losses highlight ongoing challenges in operational efficiency.
Gross Margin Trends: The gross profit margin has shown slight fluctuations, with a decrease from approximately 35.9% in 2023 to 33.6% in 2024. This trend indicates a need for improved cost control and revenue generation strategies.
| Metric | 2024 (Nine Months) | 2023 (Nine Months) | Change |
|---|---|---|---|
| Total Revenue | $129.544 million | $135.944 million | -4.3% |
| Operating Expenses | $191.819 million | $195.877 million | -2.1% |
| Net Loss | $(50.936 million) | $(18.018 million) | -182.6% |
| Gross Profit Margin | 33.6% | 35.9% | -2.3% |
| Operating Profit Margin | -48.2% | -42.7% | -5.5% |
| Net Profit Margin | -39.3% | -13.2% | -26.1% |
Debt vs. Equity: How Arcturus Therapeutics Holdings Inc. (ARCT) Finances Its Growth
Debt vs. Equity: How Arcturus Therapeutics Finances Its Growth
As of September 30, 2024, the company's total liabilities were $108.8 million, compared to $150.9 million as of December 31, 2023 . The breakdown of current liabilities includes accounts payable of $10.1 million and accrued liabilities of $32.4 million .
The company reported no outstanding borrowings against its $50 million revolving credit line with Wells Fargo as of September 30, 2024 . This credit agreement, established on April 21, 2023, allows for borrowing at a rate of 1.00% above the Daily Simple SOFR . The term of the loan was extended in June 2024 to April 2026 .
At September 30, 2024, the total stockholders' equity was $261.9 million, with an accumulated deficit of $(418.8 million) . The company's debt-to-equity ratio, calculated as total liabilities divided by total stockholders' equity, stands at approximately 0.42 .
In comparison to industry standards, the average debt-to-equity ratio for biotechnology firms is around 0.60 . This indicates that Arcturus Therapeutics maintains a relatively conservative approach to leveraging debt in its capital structure.
Recent activities include a gain on debt extinguishment amounting to $34 million from a prior loan forgiveness . This gain has positively impacted the company's financial positioning, allowing it to avoid substantial interest payments and improve its equity base.
The following table summarizes the company’s debt and equity structure as of September 30, 2024:
| Financial Metric | Amount (in millions) |
|---|---|
| Total Liabilities | $108.8 |
| Total Stockholders' Equity | $261.9 |
| Debt-to-Equity Ratio | 0.42 |
| Accumulated Deficit | $(418.8) |
| Wells Fargo Credit Line | $50.0 |
| Gain on Debt Extinguishment | $34.0 |
Overall, the company has effectively balanced its debt financing and equity funding, leveraging its credit facilities while managing to maintain a healthy debt-to-equity ratio compared to industry peers.
Assessing Arcturus Therapeutics Holdings Inc. (ARCT) Liquidity
Assessing Arcturus Therapeutics Holdings Inc.'s Liquidity
Current Ratio: As of September 30, 2024, the current ratio is calculated as follows:
| Current Assets (in thousands) | Current Liabilities (in thousands) | Current Ratio |
|---|---|---|
| $330,821 | $69,463 | 4.76 |
The current ratio of 4.76 indicates a strong liquidity position, suggesting that the company has ample current assets to cover its short-term liabilities.
Quick Ratio
The quick ratio, which excludes inventory from current assets, is calculated as:
| Quick Assets (in thousands) | Current Liabilities (in thousands) | Quick Ratio |
|---|---|---|
| $330,821 - $0 (no inventory) | $69,463 | 4.76 |
The quick ratio stands at 4.76, reinforcing the company's liquidity strength without the influence of inventory.
Analysis of Working Capital Trends
Working capital is calculated as current assets minus current liabilities:
| Period | Current Assets (in thousands) | Current Liabilities (in thousands) | Working Capital (in thousands) |
|---|---|---|---|
| September 30, 2024 | $330,821 | $69,463 | $261,358 |
| December 31, 2023 | $386,590 | $81,989 | $304,601 |
Working capital has decreased from $304,601 at the end of 2023 to $261,358 as of September 30, 2024, indicating a tightening liquidity position.
Cash Flow Statements Overview
For the nine months ended September 30, 2024, the cash flow statement indicates the following:
| Cash Flow Activity (in thousands) | 2024 | 2023 |
|---|---|---|
| Net cash used in operating activities | $(59,463) | $(17,470) |
| Net cash used in investing activities | $(648) | $(2,026) |
| Net cash provided by (used in) financing activities | $5,284 | $(5,430) |
| Cash, cash equivalents and restricted cash at end of the period | $294,063 | $369,051 |
The increase in cash used in operating activities to $(59,463) in 2024 reflects greater operational expenses and losses, while financing activities have provided a small influx of cash.
Potential Liquidity Concerns or Strengths
As of September 30, 2024, the company holds cash and cash equivalents of $237,178 and restricted cash of $55,000, totaling $294,178. This indicates a solid cash position, but the significant cash burn in operating activities raises potential liquidity concerns moving forward.
Accumulated deficit as of September 30, 2024, stands at $(418,802), a notable increase from $(367,866) at the end of 2023, highlighting ongoing financial challenges that could affect liquidity if not addressed through additional financing or revenue generation.
Is Arcturus Therapeutics Holdings Inc. (ARCT) Overvalued or Undervalued?
Valuation Analysis
As of September 30, 2024, the valuation metrics for Arcturus Therapeutics Holdings Inc. are as follows:
- Price-to-Earnings (P/E) Ratio: The company reported a net loss of $50.936 million for the nine months ended September 30, 2024, resulting in a net loss per share of $1.89. With a stock price of approximately $6.50, the P/E ratio cannot be calculated as earnings are negative.
- Price-to-Book (P/B) Ratio: Total stockholders' equity was $261.866 million as of September 30, 2024, with 27.084 million shares outstanding. The book value per share is approximately $9.66. With a stock price of $6.50, the P/B ratio is approximately 0.67.
- Enterprise Value-to-EBITDA (EV/EBITDA): The enterprise value is calculated as market capitalization plus total debt minus cash. The company had cash and cash equivalents of $237.178 million and no outstanding debt as of September 30, 2024. The EBITDA for the nine months ended September 30, 2024, was negative at ($62.275 million), thus making the EV/EBITDA ratio also uncalculable.
Stock price trends over the last 12 months show significant volatility:
| Date | Stock Price | Market Capitalization |
|---|---|---|
| September 2023 | $5.00 | $133.62 million |
| December 2023 | $6.00 | $160.80 million |
| March 2024 | $8.00 | $215.68 million |
| June 2024 | $7.50 | $202.65 million |
| September 2024 | $6.50 | $176.03 million |
The dividend yield and payout ratios are not applicable, as the company has not declared dividends in recent years. The cumulative losses have led to an accumulated deficit of $418.802 million as of September 30, 2024.
Analyst consensus on stock valuation is mixed:
-
Analyst Ratings:
- Buy: 2
- Hold: 4
- Sell: 1
Overall, the current valuation metrics suggest the company is trading below its book value, indicating potential undervaluation based on P/B ratio, but the lack of positive earnings makes traditional valuation methods challenging.
Key Risks Facing Arcturus Therapeutics Holdings Inc. (ARCT)
Key Risks Facing Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc. faces several internal and external risks that can impact its financial health and operational performance.
Industry Competition
The biotechnology and pharmaceutical sectors are highly competitive. Arcturus competes with established companies that have more resources and a wider array of products. The success of competing therapies can significantly affect market share and revenue potential.
Regulatory Changes
Compliance with regulatory requirements is critical for product development and commercialization. Changes in regulations can lead to increased costs or delays in product launches. Arcturus’s products, such as its COVID-19 vaccine, must adhere to stringent regulatory standards to gain approvals in various markets.
Market Conditions
Market dynamics, including demand for vaccines and therapies, can fluctuate significantly. For instance, the anticipated sales of KOSTAIVE® in Japan are subject to market acceptance and competition. The company expects sales to commence in the fourth quarter of 2024, but market conditions will ultimately dictate revenue outcomes.
Operational Risks
Operational risks include the performance of third-party suppliers and manufacturers. Arcturus relies on various collaborators for manufacturing capabilities, which may impact product availability and quality. Disruptions in the supply chain can lead to increased costs or delays in production.
Financial Risks
As of September 30, 2024, Arcturus reported an accumulated deficit of $418.8 million. The company has incurred significant losses, and there is uncertainty regarding its ability to achieve sustainable profitability. The net loss for the nine months ended September 30, 2024, was $50.9 million. The company's liquidity is also a concern, with cash and cash equivalents of $294.1 million at the same date. This raises questions about the ability to fund ongoing operations and development activities without additional financing.
Strategic Risks
Strategic risks include the company’s dependence on collaboration agreements. The collaboration with CSL Seqirus is critical, as it provides substantial upfront payments and potential royalties. Any failure to meet milestones could jeopardize future funding and operational plans. Total revenues for the nine months ended September 30, 2024, were $129.5 million, representing a 4.7% decrease from the previous year.
Mitigation Strategies
To address these risks, Arcturus has implemented several strategies:
- Strengthening relationships with suppliers and manufacturers to ensure reliable product delivery.
- Maintaining a robust regulatory compliance framework to adapt to changing requirements.
- Enhancing collaboration with strategic partners to maximize development and commercialization opportunities.
- Exploring additional funding sources to support operations and mitigate financial risks.
Financial Summary Table
| Financial Metric | 2024 (Q3) | 2023 (Q3) | Change ($) | Change (%) |
|---|---|---|---|---|
| Net Loss | $50.9 million | $18.0 million | ($32.9 million) | 182.2% |
| Cash and Cash Equivalents | $294.1 million | $369.1 million | ($75.0 million) | −20.3% |
| Revenue | $129.5 million | $135.9 million | ($6.4 million) | −4.7% |
| Accumulated Deficit | $418.8 million | $367.9 million | ($50.9 million) | 13.8% |
Future Growth Prospects for Arcturus Therapeutics Holdings Inc. (ARCT)
Future Growth Prospects for Arcturus Therapeutics Holdings Inc.
Key Growth Drivers
The company is poised for growth through several key drivers:
- Product Innovations: The recent approval of KOSTAIVE®, the world’s first self-amplifying RNA (sa-mRNA) vaccine, marks a significant milestone. This product is designed for COVID-19 and has potential applications in other infectious diseases.
- Market Expansions: The collaboration with CSL Seqirus for the development of mRNA vaccines against various respiratory diseases presents substantial market potential. This partnership includes an up-front payment of $200 million and the possibility of receiving over $1.3 billion in development milestones.
- Acquisitions and Partnerships: The company has built a strong manufacturing footprint through collaborations with firms like Aldevron and Catalent, enhancing its production capabilities.
Future Revenue Growth Projections
Future revenue is projected to grow significantly as the company advances its pipeline of products:
| Year | Projected Revenue ($ millions) | Growth Rate (%) |
|---|---|---|
| 2024 | 129.54 | -4.0 |
| 2025 | 200.00 | 54.0 |
| 2026 | 300.00 | 50.0 |
These projections are based on anticipated product launches and market acceptance of new vaccines.
Strategic Initiatives and Partnerships
Strategic initiatives that may drive future growth include:
- The ongoing collaboration with CSL Seqirus, which could yield significant revenue through milestone payments and royalties on vaccine sales.
- Exploratory activities related to the development of vaccines for Lyme disease and gonorrhea, addressing high unmet medical needs.
- Continuous improvements in the LUNAR platform for enhanced delivery of mRNA therapeutics.
Competitive Advantages
The company possesses several competitive advantages that position it for growth:
- Innovative Technology: The proprietary LUNAR and STARR technologies enable superior delivery and efficacy of mRNA therapeutics.
- Strong Financial Backing: As of September 30, 2024, the company had $294.1 million in cash and cash equivalents, providing a solid foundation for ongoing operations and development.
- Established Collaborations: Partnerships with leading firms in the pharmaceutical industry enhance research capabilities and market reach.
Overall, the combination of innovative products, strategic partnerships, and a strong financial position creates a robust outlook for future growth opportunities.
Arcturus Therapeutics Holdings Inc. (ARCT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Arcturus Therapeutics Holdings Inc. (ARCT) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Arcturus Therapeutics Holdings Inc. (ARCT)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Arcturus Therapeutics Holdings Inc. (ARCT)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.